Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive,Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed.
An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitusis a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.
Here is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It features recent major diabetes and lipid related clinical trials, and includes tables and figures to highlight major points.
Arvustused
From the book reviews: "This volume reviews in 23 chapters the lipid and lipoprotein changes induced by diabetes mellitus. It contains didactic color illustrations and many references. For clinical and research diabetologists, pharmacologists and biochemists." (Pediatric Endocrinology Reviews (PER), Vol. 12 (1), September, 2014)
Ch1: Laboratory Assessment of Lipoproteins in Diabetes
David R. Sullivan
Barry Lewis
Ch2: Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin
Resistance Diabetes
Michael Cobble
Patrick D. Mize
Eliot A. Brinton
Ch3: Insulin Resistance and Atherosclerosis
Kamalpreet Singh
Vasudevan A. Raghavan
Ch4: Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism
in the Setting of Type 2 Diabetes
Thomas D. Dayspring
Ch5: Lipoprotein Metabolism and Alterations induced by insulin resistance and
diabetes
Gerald H. Tomkin
Daphne Owens
Ch6: Production and Metabolism of Triglyceride-Rich Lipoproteins in both the
Normal and Diabetic
States
Angela Pirillo
Giuseppe D. Norata
Alberico L. Catapano
Ch7: Lipoprotein(a): Structure, Metabolism and Pathophysiology
Alicia J. Jenkins
Karam M. Kostner
Gerhard M. Kostner
Ch8: Lipoprotein Glycation in Diabetes Mellitus
Alicia J. Jenkins
Richard L. Klein
Andrzej S. Januszewski
Ch9: Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus
Marielle Kaplan
Michael Aviram
Tony Hayek
Ch10: The Role of Modified Forms of LDL and Corresponding Autoantibodies in
the Development of Complications in Diabetes
Maria F. Lopes-Virella
Gabriel Virella
Ch11: Lipid Extracellular Matrix Interactions as Therapeutic Targets in the
Atherosclerosis of Diabetes
Narin Osman
Peter J.
Little
Ch12: Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus
Richard L. Klein
Ch13: Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes:
Pathogenesis, Significance and Therapy
Sandra J. Hamilton
Gerald F. Watts
Ch14: Lipoproteins and Diabetic Nephropathy
Ville-Petteri Mäkinen
Nina Tolonen
Per-Henrik Groop
Ch15: Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic
Retinopathy
Mingyuan Wu
Timothy J. Lyons
Ch16: Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic
Control on Lipoporteins in Diabetes
Peter Clifton
Ch17: About Randomised Clinical Trials Related to Lipoproteins in Diabetes
Mellitus
Anthony Keech
Alicia J. Jenkins
Val Gebski
Ch18: Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in
Diabetic Patients
Seth S. Martin
Parag H. Joshi
Steven R. Jones
Ch19: The PPAR System in Diabetes
Jean Claude Ansquer
Christelle Foucher
Ch20: Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in
Diabetic Patients
Eliot A. Brinton
Ch21: Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in
Diabetic Patients
Henry A. Tran
Arthur Z. Schwartzbard
James A. Underberg
Ch22: Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding
Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with
Diabetes Mellitus
Harold Bays
Ch23: Emerging Lipoprotein-Related Therapeutics for Patients with
Diabetes
Peter J. Little
Alan Chait
Andrzej S. Januszewski
Alex Bobik
David ONeal
Alicia J. Jenkins
Alicia Jenkins, MBBS, MD, FRACP, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USA
Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC CGH Medical Center, Sterling, IL University of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, IL Michigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USA
Timothy J. Lyons, MD, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA
